Literature DB >> 16518832

Molecular regulation of androgen action in prostate cancer.

Scott M Dehm1, Donald J Tindall.   

Abstract

Androgens are critical regulators of prostate differentiation and function, as well as prostate cancer growth and survival. Therefore, androgen ablation is the preferred systemic treatment for disseminated prostate cancer. Androgen action is exerted in target tissues via binding the androgen receptor (AR), a nuclear receptor transcription factor. Historically, the gene expression program mediated by the AR has been poorly understood. However, recent gene expression profiling and more traditional single-gene characterization studies have revealed many androgen-regulated genes that are important mediators of androgen action in both normal and malignant prostate tissue. This review will focus on the androgen-regulated gene expression program, and examine how recently identified androgen-regulated genes are likely to contribute to the development and progression of prostate cancer. We will also summarize several recent studies that have attempted to unravel how these genes are deregulated in androgen depletion independent prostate cancer. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518832     DOI: 10.1002/jcb.20794

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  110 in total

1.  The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.

Authors:  Smita Awasthi; Heather Ezelle; Bret A Hassel; Anne W Hamburger
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

Review 2.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

3.  Androgen modulation of coregulator expression in prostate cancer cells.

Authors:  Hannelore V Heemers; Kevin M Regan; Lucy J Schmidt; S Keith Anderson; Karla V Ballman; Donald J Tindall
Journal:  Mol Endocrinol       Date:  2009-01-22

4.  Interrelation of androgen receptor and miR-30a and miR-30a function in ER-, PR-, AR+ MDA-MB-453 breast cancer cells.

Authors:  Shuhua Lyu; Han Liu; Xia Liu; Shan Liu; Yahong Wang; Qi Yu; Yun Niu
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

5.  MicroRNA-381 suppresses proliferation and invasion of prostate cancer cells through downregulation of the androgen receptor.

Authors:  Xin Rui; Ting-Ting Gu; Hua-Feng Pan; Si-Liang Shao; Hong-Xiang Shao
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

6.  Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics.

Authors:  Young Ah Goo; Alvin Y Liu; Soyoung Ryu; Scott A Shaffer; Lars Malmström; Laura Page; Liem T Nguyen; Catalin E Doneanu; David R Goodlett
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

7.  SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells.

Authors:  Jenna D Lovaas; Lijia Zhu; Christine Y Chiao; Vanessa Byles; Douglas V Faller; Yan Dai
Journal:  Prostate       Date:  2012-10-04       Impact factor: 4.104

8.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

9.  NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Authors:  Maria Papaioannou; Sonja Schleich; Daniela Roell; Undine Schubert; Tamzin Tanner; Frank Claessens; Rudolf Matusch; Aria Baniahmad
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

Review 10.  The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Authors:  Donald J Tindall; Roger S Rittmaster
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.